Is FMC Corporation (NYSE:FMC) a buy in 2026?
Hold. FMC Corporation is a wait-and-watch at today's price, not a fresh buy.
Cheap on paper, broken on the ground. FMC needs a generic glyphosate-style cycle to turn before this book value bargain becomes real.
Where FMC is headed
FMC at $12.72 is trading at roughly half book value with a 252% debt-to-equity ratio, a market cap that's collapsed from $11B to $1.6B over five years, and a generic competitor problem that won't fix itself in two quarters. The story the market is telling: this is a melting ice cube of a crop chemistry portfolio losing patent protection to Chinese generics while sitting on a debt load that looks more like a leveraged buyout than an industrial. The story management is selling: Plinazolin, fluindapyr, and the diamide successor pipeline (Rynaxypyr's heir) will re-anchor the franchise by 2027, while inventory destocking in Latin America (the worst of it through 2024-2025) finally normalises.
Read the full Compass Direction on FMC
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $11.50).
See the full FMC analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is FMC Corporation (NYSE:FMC) a buy in 2026?
Hold. FMC Corporation is a wait-and-watch at today's price, not a fresh buy. Cheap on paper, broken on the ground. FMC needs a generic glyphosate-style cycle to turn before this book value bargain becomes real.
What is FMC's Compass Score?
FMC Corporation scores 24/100 on Alexandria's Compass, placing it in the "Headwinds" tier. Scores blend eight factors and update weekly.
What is the price target for FMC?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the FMC page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.